Every Cure’s Unconventional Drug Repurposing Approach Could Reshape Rare Disease Treatment

The non-profit Every Cure, founded by David Fajgenbaum, is pursuing a novel drug repurposing strategy in rare diseases that diverges from traditional biotech research models. The initiative may influence future approaches to treating rare conditions, though specific outcomes remain unquantified.

• Every Cure is a non-profit focused on drug repurposing for rare diseases
• Founded by David Fajgenbaum, the initiative challenges traditional biotech R&D models
• The strategy prioritizes existing, approved drugs over novel compound development
• No specific financial figures, trial results, or FDA approvals are mentioned in the source
• The approach aims to accelerate treatment access for underserved patient populations
• The model may influence future biotech investment and R&D trends